If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com. The FDA is set to review ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...

Moderna is up 87.7% since the beginning of the year, and at $57.93 per share, has set a new 52-week high. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an ...

Moderna (MRNA) closed the most recent trading day at $52.56, moving -1.55% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.61% for the day.

The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.

Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50. Today they’ve nudged back to about $53 — but ...